Zoetis (NYSE:ZTS) Trading 0.9% Higher

Zoetis Inc. (NYSE:ZTS)’s stock price traded up 0.9% during trading on Thursday . The stock traded as high as $153.67 and last traded at $152.86. 1,057,616 shares were traded during trading, a decline of 64% from the average session volume of 2,938,021 shares. The stock had previously closed at $151.51.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Piper Sandler reiterated an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday. The Goldman Sachs Group boosted their price target on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Barclays boosted their price target on shares of Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a report on Wednesday, February 14th. Finally, Stifel Nicolaus lowered their price target on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $221.75.

Zoetis Trading Up 0.6 %

The company’s fifty day moving average price is $177.35 and its two-hundred day moving average price is $180.39. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The firm has a market cap of $69.69 billion, a P/E ratio of 30.15, a price-to-earnings-growth ratio of 2.34 and a beta of 0.85.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same period in the previous year, the company posted $1.15 EPS. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. As a group, sell-side analysts predict that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.13%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio is currently 34.12%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at approximately $4,037,257.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.12% of the company’s stock.

Institutional Investors Weigh In On Zoetis

A number of hedge funds have recently added to or reduced their stakes in the stock. Hohimer Wealth Management LLC grew its holdings in Zoetis by 1.2% during the 4th quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock worth $866,000 after acquiring an additional 52 shares during the last quarter. Enterprise Financial Services Corp lifted its position in Zoetis by 2.3% during the 1st quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company’s stock valued at $407,000 after purchasing an additional 55 shares during the period. Forum Financial Management LP lifted its position in Zoetis by 0.8% during the 4th quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock valued at $1,458,000 after purchasing an additional 56 shares during the period. Angeles Wealth Management LLC lifted its position in Zoetis by 3.5% during the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock valued at $324,000 after purchasing an additional 56 shares during the period. Finally, Prossimo Advisors LLC lifted its position in Zoetis by 1.7% during the 4th quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock valued at $690,000 after purchasing an additional 57 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.